Compare WWD & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WWD | RPRX |
|---|---|---|
| Founded | 1870 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 16.4B |
| IPO Year | N/A | 2020 |
| Metric | WWD | RPRX |
|---|---|---|
| Price | $332.32 | $39.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $298.18 | $45.75 |
| AVG Volume (30 Days) | 530.4K | ★ 3.3M |
| Earning Date | 02-02-2026 | 02-10-2026 |
| Dividend Yield | 0.33% | ★ 2.37% |
| EPS Growth | ★ 19.63 | N/A |
| EPS | ★ 7.19 | 1.75 |
| Revenue | ★ $3,567,064,000.00 | $2,349,844,000.00 |
| Revenue This Year | $12.28 | $37.66 |
| Revenue Next Year | $8.54 | $2.34 |
| P/E Ratio | $46.73 | ★ $22.68 |
| Revenue Growth | ★ 7.30 | 3.70 |
| 52 Week Low | $146.82 | $29.66 |
| 52 Week High | $338.17 | $41.70 |
| Indicator | WWD | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.58 | 49.50 |
| Support Level | $321.99 | $39.87 |
| Resistance Level | $338.17 | $40.58 |
| Average True Range (ATR) | 7.88 | 0.78 |
| MACD | 0.77 | -0.03 |
| Stochastic Oscillator | 83.27 | 34.46 |
Woodward Inc is an independent designer, manufacturer, and service provider of control solutions for the aerospace and industrial markets. It designs, produces, and services reliable, efficient, low-emission, and high-performance energy control products for diverse applications in challenging environments. The company operates in two segments, Aerospace and Industrial. The Aerospace segment provides fuel pumps, actuators, air valves, specialty valves, fuel nozzles, and thrust reverser actuation systems for turbine engines and nacelles, and flight deck controls, actuators, servo controls, motors, and sensors for aircraft. The Industrial segment offers actuators, valves, pumps, fuel injection systems, solenoids, ignition systems, speed controls, electronics and software, and sensors.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.